AskBio CEO and Co-Founder Sheila Mikhail Receives 2022 Entrepreneurship Award from University of Chicago Booth School of Business

“This award is extremely meaningful because Booth School of Business is one of the highest ranked business schools in the country,” said the co-founder and CEO of AskBio. Sheila Mikhail. “The award is a reflection of accomplishments that would not have been possible without the support of a world-class team at AskBio as we continue to advance our research, clinical candidates and manufacturing capabilities.”

Ms. Mikhail earned a JD with honors from Northwestern Universityan MBA in finance with honors from University of Chicagoand a BS with highest honors from University of Illinois at Urbana-Champaign. She co-founded AskBio in 2001 with Dr R. Jude Samulsky, who is considered one of the leading pioneers of AAV gene therapy technology. Since AskBio’s co-founding and under Ms. Mikhail’s leadership, the company, including its manufacturing facilities, has grown to employ more than 700 biotechnology professionals operating in five countries.

Eighteen months after the close of a Series A funding round $235 million in April 2019Ms. Mikhail orchestrated a $4 billion acquisition by Bayer AG in October 2020. Under Ms. Mikhail’s leadership, AskBio is thriving with an extensive gene therapy technology toolkit, three state-of-the-art manufacturing facilities in San Sebastian, Spain, and a robust therapeutic pipeline, the all in various clinical stages, to treat Pompe disease, limb girdle muscular dystrophy, multiple system atrophy, congestive heart failure, Huntington’s disease and Parkinson’s disease.

“In my opinion, Sheila is one of the most accomplished biotech executives in the industry,” commented Dr. Samulski, co-founder and chief scientific officer of AskBio. “The recognition by University of Chicago The Booth School of Business is a testament to its unparalleled business acumen combined with its significant mastery of genetic science.”

The Distinguished Alumni Awards are only available to Chicago Booth graduates. The Entrepreneurship Award is given to an individual who has demonstrated professional achievement of the highest caliber in managing and building a successful business and is recognized by colleagues and peers for outstanding leadership and leadership abilities. ‘administration.

About AskBio

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG acquired in 2020, is a fully integrated gene therapy company dedicated to developing life-saving drugs that cure genetic diseases. The company maintains a portfolio of clinical programs covering a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes treatments for Pompe disease, Parkinson’s disease and heart failure. congestive heart. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive library of capsids and promoters. With its global headquarters in Research Triangle Park, North Carolinaand European headquarters in Edinburgh, UK, the company has generated hundreds of proprietary capsids and promoters, several of which have entered clinical trials. Founded in 2001 and one of the earliest innovators in the field of gene therapy, the company holds more than 750 patents in areas such as AAV production and chimeric and self-complementary capsids. Learn more at or follow us on LinkedIn.

About Bayer

Bayer is a global company with core competencies in the areas of life sciences healthcare and nutrition. Its products and services are designed to help people and the planet prosper by supporting efforts to master the major challenges posed by a growing and aging global population. Bayer is committed to fostering sustainable development and generating a positive impact on its activities. At the same time, the Group aims to increase its profitability and create value through innovation and growth. The Bayer brand is synonymous with trust, reliability and quality around the world. During the 2021 financial year, the Group employed approximately 100,000 people and achieved a turnover of €44.1 billion. R&D expenses before exceptional items amounted to €5.3 billion. For more information, visit

AskBio forward-looking statements

This press release contains “forward-looking statements”. All statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes”, “anticipates”, “plans”, “expects”, “will”, “intends”, “potential”, “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding AskBio’s pipeline of development candidates, technology and manufacturing process. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio’s control. Known risks include, among others: AskBio may not be able to execute its business plans and objectives, including meeting its expected or anticipated regulatory milestones and deadlines, its reliance on third parties, its clinical development, its manufacturing processes and plans, and bringing its product candidates to market, for a variety of reasons, including the ongoing COVID-19 pandemic, possible limitations in the Company’s financial and other resources, limitations of workmanship that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our collaborators and third-party partners, and regulatory, court, or agency comments or rulings, such as the comments and rulings of the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the above risks could materially and adversely affect AskBio’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio undertakes no obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


Comments are closed.